Towa Pharmaceutical Co (6QC) fair value: what the stock is really worth
As of Oct 26, 2026: fair value (intrinsic value) of Towa Pharmaceutical Co stock €15.39, price €20.15, upside -23.6%, quality 47 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 27, 2026.
How to read this chart
60‑month range €10.23 – €24.09 · fair‑value band €7.60 – €15.39 · the €20.15 price screens above the €15.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 27, 2026.
Follow Towa Pharmaceutical Co in your weekly email
Every Wednesday you see whether Towa Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas.
Show moreShow less
It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products.
The company also offers IT service related to healthcare; disease risk testing services; and sale of quasi drugs.
In addition, it is involved in research and development and production of active pharmaceutical ingredients, intermediates, and support business; and planning, development and OEM manufacturing of health foods, pharmaceuticals, general foods, and other miscellaneous merchandizes.
Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Kadoma, Japan.
Stock analysis
Towa Pharmaceutical Co (6QC) currently trades at €20.15, while our model-based Fair Value estimate is €15.39, 23.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €16.02 per share, and 5 of the 21 models we run sit above the €20.15 price.
Bear case: the Economic Profit group reads lowest at €1.75, and 16 of the 21 models stay below the price. Data coverage for this calculation is high.
Scenario range: €7.60 (bear) to €15.39 (bull), the price of €20.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Towa Pharmaceutical Co reported revenue of ¥274B in FY2026 versus ¥166B in FY2022, a compound +13.4%/yr. Reported net income was ¥5.3B in FY2026, compounding −24.2%/yr from FY2022.
Key figures
Market cap €992M Small · P/E ratio 33.6 · P/S ratio 0.64 · EPS (TTM) €0.6000 · Dividend yield 2.3% · Net margin 1.9% · Return on equity 4.7% · Return on assets (EBIT) 4.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −24%, 6QC screens cheaper than that median.
Fair Value models
Bear€7.60Fair Value €15.39Bull€15.39
Price €20.15 · Upside -23.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (€0.0839 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.4%
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.8%
Dividend (yield on the price)2.3%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 8%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about +29.7% a year for the price and +5.8% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 583 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−23.6% · Below median
Profitability
Return on equity (12 months)4.7% · Below median
Return on assets1.1% · Below median
Net margin (12 months)3.0% · Below median
Operating margin (12 months)9.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)9.6% · Above median
Dividend yield (12 months)2.3% · Above median
Balance sheet
Debt / equity1.03× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Towa Pharmaceutical Co Fair Value". https://www.fairvalue-calculator.com/stock/6QC
Frequently asked questions
Is Towa Pharmaceutical Co (6QC) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of €15.39 versus a price of €20.15, about −24% upside (overvalued).
What is the fair value of 6QC?
Our model-based fair value for Towa Pharmaceutical Co is €15.39 (as of Oct 27, 2026), built from audited fundamentals. The current price: €20.15.
What is the quality score of 6QC?
Towa Pharmaceutical Co has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Towa Pharmaceutical Co (6QC)?
Our model-based price target is the fair value of €15.39 (as of Oct 27, 2026) from 25 valuation models. Cautious scenario €7.60, optimistic scenario €15.39. It is a calculation from audited fundamentals, not an analyst target.
What is the Towa Pharmaceutical Co stock forecast for 2026?
Our models put fair value at €15.39, about −24% upside versus a price of €20.15 (overvalued). Cautious scenario €7.60, optimistic scenario €15.39. The calculation is refreshed regularly with new filings.
What is the revenue of Towa Pharmaceutical Co (6QC)?
Towa Pharmaceutical Co reported trailing-twelve-month revenue of about ¥280B (latest available figure, as of Oct 27, 2026).
Does Towa Pharmaceutical Co pay a dividend?
Towa Pharmaceutical Co currently shows a dividend yield of 2.25% relative to its recent price (as of Oct 27, 2026).
What growth is priced into Towa Pharmaceutical Co (6QC)?
For today's price to be fair in a discounted-cash-flow model, Towa Pharmaceutical Co would have to grow free cash flow by +32.4 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +13.4 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of 6QC use?
Our models discount Towa Pharmaceutical Co at 11.0 %: a base by market capitalisation (small), country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Towa Pharmaceutical Co that is +32.4 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Towa Pharmaceutical Co (6QC) delivered so far?
Over the past 4 years revenue at Towa Pharmaceutical Co grew +13.4 % a year. The price currently implies +32.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Towa Pharmaceutical Co (6QC) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into Towa Pharmaceutical Co (+32.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Towa Pharmaceutical Co (6QC)?
The free-cash-flow yield on the price is 3.61 %: that much free cash flow Towa Pharmaceutical Co produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Towa Pharmaceutical Co (6QC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Towa Pharmaceutical Co it is €15.39 per share (as of Oct 27, 2026), against a price of €20.15. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Towa Pharmaceutical Co stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 6QC trades above its calculated fair value: price €20.15, fair value €15.39, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6QC?
No. The price is what the market pays today (€20.15); the fair value is what the company's own numbers justify (€15.39). For Towa Pharmaceutical Co the two are €4.76 per share apart. That gap is exactly why we show both numbers side by side.
How much is Towa Pharmaceutical Co worth?
The market values Towa Pharmaceutical Co at about €992M (market capitalisation, as of Oct 27, 2026). Per share that is €20.15; our models calculate a fair value of €15.39 per share.
What do the bullish and bearish scenarios say about 6QC?
Our models span a range for Towa Pharmaceutical Co: cautious scenario €7.60, base €15.39, optimistic €15.39 per share (as of Oct 27, 2026, price €20.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6QC?
Towa Pharmaceutical Co trades at a price-to-earnings ratio of 33.6 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €15.39 is built from several models across several years. Other multiples: P/B 1.0, P/S 0.6, EV/EBITDA 6.6.
How solid is the balance sheet of Towa Pharmaceutical Co (6QC)?
Balance-sheet figures for Towa Pharmaceutical Co (as of Oct 27, 2026): return on equity 4.7%, debt of 1.03 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 6QC from its 52-week high?
Towa Pharmaceutical Co trades at €20.15, about 13% below its 52-week high of €23.10 and 35% above the low of €14.88 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of €15.39 is for.
Which stocks are comparable to Towa Pharmaceutical Co?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Towa Pharmaceutical Co stock attractive at the current price?
The data as of Oct 27, 2026: price €20.15, calculated fair value €15.39 (−24%), Quality Score 47/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6QC calculated?
We run Towa Pharmaceutical Co through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €15.39, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. Towa Pharmaceutical Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Towa Pharmaceutical Co (6QC)?
The closing price on Oct 26, 2026 was €20.15. Our model-based fair value is €15.39, about −24% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Towa Pharmaceutical Co right now?
The price sits above even our optimistic bull case (€15.39). The favourable scenario is already priced in. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€7.60 to €15.39) leaves room in how you read the outcome.
Key figures of Towa Pharmaceutical Co
How large is the market capitalisation of Towa Pharmaceutical Co (6QC)?
The market capitalisation of Towa Pharmaceutical Co is €992M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Towa Pharmaceutical Co (6QC)?
The price-to-sales ratio of Towa Pharmaceutical Co is 0.64 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Towa Pharmaceutical Co (6QC)?
Earnings per share at Towa Pharmaceutical Co are €0.6000 (price ÷ EPS = P/E 33.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Towa Pharmaceutical Co (6QC)?
The dividend yield of Towa Pharmaceutical Co is 2.3% (payout 75.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Towa Pharmaceutical Co (6QC)?
The net margin of Towa Pharmaceutical Co is 1.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Towa Pharmaceutical Co (6QC)?
The return on equity (ROE) of Towa Pharmaceutical Co is 4.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Towa Pharmaceutical Co (6QC)?
On an EBIT basis the return on assets of Towa Pharmaceutical Co is 4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Towa Pharmaceutical Co (6QC)?
The operating margin of Towa Pharmaceutical Co is 9.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Towa Pharmaceutical Co (6QC)?
Revenue at Towa Pharmaceutical Co is growing +9.6% versus a year earlier (3y avg +9.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Towa Pharmaceutical Co (6QC)?
Earnings per share at Towa Pharmaceutical Co are growing +120% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Towa Pharmaceutical Co (6QC) carry?
The net debt of Towa Pharmaceutical Co is ¥167B (fiscal year 2026, ≈ 26.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Towa Pharmaceutical Co in the live analysis
One click puts Towa Pharmaceutical Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 27, 2026